Literature DB >> 23123670

Neutral solution low in glucose degradation products is associated with less peritoneal fibrosis and vascular sclerosis in patients receiving peritoneal dialysis.

Kunio Kawanishi1, Kazuho Honda, Misao Tsukada, Hideaki Oda, Kosaku Nitta.   

Abstract

BACKGROUND: The effects of novel biocompatible peritoneal dialysis (PD) solutions on human peritoneal membrane pathology have yet to be determined. Quantitative evaluation of human peritoneal biopsy specimens may reveal the effects of the new solutions on peritoneal membrane pathology. ♢
METHODS: Peritoneal specimens from 24 PD patients being treated with either acidic solution containing high-glucose degradation products [GDPs (n = 12)] or neutral solution with low GDPs (n = 12) were investigated at the end of PD. As controls, pre-PD peritoneal specimens, obtained from 13 patients at PD catheter insertion, were also investigated. The extent of peritoneal fibrosis, vascular sclerosis, and advanced glycation end-product (AGE) accumulation were evaluated by quantitative or semi-quantitative methods. The average densities of CD31-positive vessels and podoplanin-positive lymphatic vessels were also determined. ♢
RESULTS: Peritoneal membrane fibrosis, vascular sclerosis, and AGE accumulation were significantly suppressed in the neutral group compared with the acidic group. The neutral group also showed lower peritoneal equilibration test scores and preserved ultrafiltration volume. The density of blood capillaries, but not of lymphatic capillaries, was significantly increased in the neutral group compared with the acidic and pre-PD groups. ♢
CONCLUSIONS: Neutral solutions with low GDPs are associated with less peritoneal membrane fibrosis and vascular sclerosis through suppression of AGE accumulation. However, contrary to expectation, blood capillary density was increased in the neutral group. The altered contents of the new PD solutions modified peritoneal membrane morphology and function in patients undergoing PD.

Entities:  

Keywords:  AGEs; GDPs; angiogenesis; biocompatible solution; peritoneal fibrosis; vascular sclerosis

Mesh:

Substances:

Year:  2012        PMID: 23123670      PMCID: PMC3649892          DOI: 10.3747/pdi.2011.00270

Source DB:  PubMed          Journal:  Perit Dial Int        ISSN: 0896-8608            Impact factor:   1.756


  29 in total

1.  New animal models for encapsulating peritoneal sclerosis--role of acidic solution.

Authors:  H Nakamoto; H Imai; Y Ishida; Y Yamanouchi; T Inoue; H Okada; H Suzuki
Journal:  Perit Dial Int       Date:  2001       Impact factor: 1.756

2.  Mesenchymal conversion of mesothelial cells as a mechanism responsible for high solute transport rate in peritoneal dialysis: role of vascular endothelial growth factor.

Authors:  Luiz S Aroeira; Abelardo Aguilera; Rafael Selgas; Marta Ramírez-Huesca; M Luisa Pérez-Lozano; Antonio Cirugeda; M Auxiliadora Bajo; Gloria del Peso; José A Sánchez-Tomero; José A Jiménez-Heffernan; Manuel López-Cabrera
Journal:  Am J Kidney Dis       Date:  2005-11       Impact factor: 8.860

3.  Accumulation of advanced glycation end products in the peritoneal vasculature of continuous ambulatory peritoneal dialysis patients with low ultra-filtration.

Authors:  K Honda; K Nitta; S Horita; W Yumura; H Nihei; R Nagai; K Ikeda; S Horiuchi
Journal:  Nephrol Dial Transplant       Date:  1999-06       Impact factor: 5.992

4.  Bicarbonate/lactate-based peritoneal dialysis solution increases cancer antigen 125 and decreases hyaluronic acid levels.

Authors:  S Jones; C J Holmes; R T Krediet; R Mackenzie; D Faict; A Tranaeus; J D Williams; G A Coles; N Topley
Journal:  Kidney Int       Date:  2001-04       Impact factor: 10.612

Review 5.  The physiological role of endoglin in the cardiovascular system.

Authors:  José M López-Novoa; Carmelo Bernabeu
Journal:  Am J Physiol Heart Circ Physiol       Date:  2010-07-23       Impact factor: 4.733

6.  Vascular proliferation and enhanced expression of endothelial nitric oxide synthase in human peritoneum exposed to long-term peritoneal dialysis.

Authors:  Sophie Combet; Toshio Miyata; Pierre Moulin; Dominique Pouthier; Eric Goffin; Olivier Devuyst
Journal:  J Am Soc Nephrol       Date:  2000-04       Impact factor: 10.121

7.  Lymphatic vessels develop during tubulointerstitial fibrosis.

Authors:  Izumi Sakamoto; Yasuhiko Ito; Masashi Mizuno; Yasuhiro Suzuki; Akiho Sawai; Akio Tanaka; Shoichi Maruyama; Yoshifumi Takei; Yukio Yuzawa; Seiichi Matsuo
Journal:  Kidney Int       Date:  2009-01-14       Impact factor: 10.612

8.  Long-term exposure to new peritoneal dialysis solutions: Effects on the peritoneal membrane.

Authors:  Siska Mortier; Dirk Faict; Casper G Schalkwijk; Norbert H Lameire; An S De Vriese
Journal:  Kidney Int       Date:  2004-09       Impact factor: 10.612

Review 9.  Peritoneal angiogenesis in response to dialysis fluid.

Authors:  Bengt Rippe
Journal:  Contrib Nephrol       Date:  2009-06-03       Impact factor: 1.580

10.  In vitro effects of bicarbonate and bicarbonate-lactate buffered peritoneal dialysis solutions on mesothelial and neutrophil function.

Authors:  N Topley; D Kaur; M M Petersen; A Jörres; J D Williams; D Faict; C J Holmes
Journal:  J Am Soc Nephrol       Date:  1996-02       Impact factor: 10.121

View more
  21 in total

1.  Re: Cancer antigen 125 as a biomarker in peritoneal dialysis: mesothelial cell health or death?

Authors:  J M Bargman
Journal:  Perit Dial Int       Date:  2013 Nov-Dec       Impact factor: 1.756

2.  Cancer antigen 125 as a biomarker in peritoneal dialysis: mesothelial cell health or death?

Authors:  R T Krediet
Journal:  Perit Dial Int       Date:  2013 Nov-Dec       Impact factor: 1.756

3.  Morphological characteristics in peritoneum in patients with neutral peritoneal dialysis solution.

Authors:  Chieko Hamada; Kazuho Honda; Kunio Kawanishi; Hirotaka Nakamoto; Yasuhiko Ito; Tsutomu Sakurada; Yudo Tanno; Toru Mizumasa; Masanobu Miyazaki; Misaki Moriishi; Masaaki Nakayama
Journal:  J Artif Organs       Date:  2015-02-14       Impact factor: 1.731

4.  Biocompatible Dialysis Solutions Preserve Peritoneal Mesothelial Cell and Vessel Wall Integrity. A Case-Control Study on Human Biopsies.

Authors:  Gloria del Peso; José Antonio Jiménez-Heffernan; Rafael Selgas; César Remón; Marta Ossorio; Antonio Fernández-Perpén; José Antonio Sánchez-Tomero; Antonio Cirugeda; Erika de Sousa; Pilar Sandoval; Raquel Díaz; Manuel López-Cabrera; María Auxiliadora Bajo
Journal:  Perit Dial Int       Date:  2015-10-16       Impact factor: 1.756

5.  Hydration Status of Patients Dialyzed with Biocompatible Peritoneal Dialysis Fluids.

Authors:  Monika Lichodziejewska-Niemierko; Michał Chmielewski; Maria Dudziak; Alicja Ryta; Bolesław Rutkowski
Journal:  Perit Dial Int       Date:  2015-10-16       Impact factor: 1.756

6.  Is the Effect of Low-GDP Solutions on Residual Renal Function Mediated by Fluid State? An Enigmatic Question which Still Needs to be Solved.

Authors:  Jeroen P Kooman; Tom Cornelis; Frank M van der Sande; Karel M L Leunissen
Journal:  Perit Dial Int       Date:  2016 May-Jun       Impact factor: 1.756

7.  Peritoneal Dialysis Fluid and Some of Its Components Potentiate Fibrocyte Differentiation.

Authors:  Sarah E Herlihy; Hannah E Starke; Melisa Lopez-Anton; Nehemiah Cox; Katayoon Keyhanian; Donald J Fraser; Richard H Gomer
Journal:  Perit Dial Int       Date:  2015-10-22       Impact factor: 1.756

8.  New Insights into the Effects of Chronic Kidney Failure and Dialysate Exposure on the Peritoneum.

Authors:  Carmen A Vlahu; Jan Aten; Marijke de Graaff; Henk van Veen; Vincent Everts; Dirk R de Waart; Dirk G Struijk; Raymond T Krediet
Journal:  Perit Dial Int       Date:  2016-05-04       Impact factor: 1.756

9.  Encapsulating peritoneal sclerosis in the era of a multi-disciplinary approach based on biocompatible solutions: the NEXT-PD study.

Authors:  Masaaki Nakayama; Masanobu Miyazaki; Kazuho Honda; Kenji Kasai; Tadashi Tomo; Hidetomo Nakamoto; Hideki Kawanishi
Journal:  Perit Dial Int       Date:  2014-02-04       Impact factor: 1.756

10.  The peritoneal-renal syndrome.

Authors:  Sharon J Nessim; Joanne M Bargman
Journal:  Nat Rev Nephrol       Date:  2013-03-19       Impact factor: 28.314

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.